Enhanced Reepithelization and Dermal Regeneration of a Novel Pongamia Oil Combination Based Chloramphenicol-Coloaded Curcumin Nanoemulsion Fortified with a Chitosan Hydrogel: Statistical Optimization, ex vivo and in vivo Studies

IF 2.7 4区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Pharmaceutical Innovation Pub Date : 2025-03-12 DOI:10.1007/s12247-025-09943-0

Bhargav E, Gowtham A, Somasekhar Reddy K, Sudheer Akkiraju

{"title":"Enhanced Reepithelization and Dermal Regeneration of a Novel Pongamia Oil Combination Based Chloramphenicol-Coloaded Curcumin Nanoemulsion Fortified with a Chitosan Hydrogel: Statistical Optimization, ex vivo and in vivo Studies","authors":"Bhargav E, Gowtham A, Somasekhar Reddy K, Sudheer Akkiraju","doi":"10.1007/s12247-025-09943-0","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>In the present study, a novel pongamia oil combination-based chloramphenicol (CPL)-coloaded curcumin (CUR) nanoemulsion (NE)-fortified chitosan hydrogel was formulated for effective wound healing.</p><h3>Methods</h3><p>The nanoemulsion was optimized by a central composite design. The factors that exhibited a significant (ANOVA) effect on the responses were studied. FT-IR and DSC studies indicated the compatibility of the drugs with excipients. The selected independent variables were Pongamia oil (PO): Tween 80: propylene glycol (PG), stirring time (ST) and sonication time, and the dependent variables selected were globule size and PDI.</p><h3>Results</h3><p>The globule size of the formulations F15a & F15b was found to be 280.23 ± 0.21 and 276.45 ± 0.29 nm, with PDIs of 0.390 ± 0.02 and 0.593 ± 0.02 and zeta potentials of -65.43 ± 0.39 and -70.73 ± 0.63 mV, which confirmed the uniform globule size distribution and stability of the formulations. Compared with the plain drugs, formulations F15a and F15b presented a greater zone of inhibition against <i>Staphylococcus aureus</i> (38 & 35 mm) and <i>E. coli</i> (32&29 mm). TEM analysis revealed a nearly spherical shape of the globules that was free from coalescence. The <i>invitro</i> drug release data indicated sustained drug release for up to 72 h. The <i>exvivo</i> drug release rates of F15a and F15b were 92.4% and 95%, respectively, for CPL and 87.6% and 94%, respectively, for CUR at 24th h. Contour plots were used to select the desired batch range. The stability studies indicated that the formulations remained stable at 40 ± 2 °C and an RH of 75 ± 5%. Compared with the control (70.00 ± 0.18%) and standard (92.04 ± 0.84%) groups, the optimized NE-CPL-CUR hydrogel F15a & F15b-treated groups exhibited greater wound contraction (94.44 ± 0.56 & 99.08 ± 0.18%) at the end of 21 days. Histopathological studies revealed better and improved reepithelization and epidermal and dermal regeneration.</p><h3>Conclusion</h3><p>The results of the present study demonstrated that the developed NE-CPL-CUR (0.5:1; CPL and CUR) chitosan-based hydrogel provided better wound healing because of the synergistic combination and presence of Pongamia oil in the nanoemulsion.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-09943-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

In the present study, a novel pongamia oil combination-based chloramphenicol (CPL)-coloaded curcumin (CUR) nanoemulsion (NE)-fortified chitosan hydrogel was formulated for effective wound healing.

Methods

The nanoemulsion was optimized by a central composite design. The factors that exhibited a significant (ANOVA) effect on the responses were studied. FT-IR and DSC studies indicated the compatibility of the drugs with excipients. The selected independent variables were Pongamia oil (PO): Tween 80: propylene glycol (PG), stirring time (ST) and sonication time, and the dependent variables selected were globule size and PDI.

Results

The globule size of the formulations F15a & F15b was found to be 280.23 ± 0.21 and 276.45 ± 0.29 nm, with PDIs of 0.390 ± 0.02 and 0.593 ± 0.02 and zeta potentials of -65.43 ± 0.39 and -70.73 ± 0.63 mV, which confirmed the uniform globule size distribution and stability of the formulations. Compared with the plain drugs, formulations F15a and F15b presented a greater zone of inhibition against Staphylococcus aureus (38 & 35 mm) and E. coli (32&29 mm). TEM analysis revealed a nearly spherical shape of the globules that was free from coalescence. The invitro drug release data indicated sustained drug release for up to 72 h. The exvivo drug release rates of F15a and F15b were 92.4% and 95%, respectively, for CPL and 87.6% and 94%, respectively, for CUR at 24th h. Contour plots were used to select the desired batch range. The stability studies indicated that the formulations remained stable at 40 ± 2 °C and an RH of 75 ± 5%. Compared with the control (70.00 ± 0.18%) and standard (92.04 ± 0.84%) groups, the optimized NE-CPL-CUR hydrogel F15a & F15b-treated groups exhibited greater wound contraction (94.44 ± 0.56 & 99.08 ± 0.18%) at the end of 21 days. Histopathological studies revealed better and improved reepithelization and epidermal and dermal regeneration.

Conclusion

The results of the present study demonstrated that the developed NE-CPL-CUR (0.5:1; CPL and CUR) chitosan-based hydrogel provided better wound healing because of the synergistic combination and presence of Pongamia oil in the nanoemulsion.

查看原文本刊更多论文

壳聚糖水凝胶强化以氯霉素-姜黄素纳米乳为基础的新型海葵油复合基姜黄素纳米乳的再上皮化和真皮再生：统计优化、体外和体内研究

目的制备一种新型甲壳聚糖水凝胶（壳聚糖水凝胶），以甲壳聚糖油复合氯霉素（CPL）载姜黄素（CUR）纳米乳为基础，用于伤口愈合。方法采用中心复合设计对纳米乳进行优化。研究了对反应有显著（ANOVA）影响的因素。傅里叶变换红外光谱（FT-IR）和DSC研究表明了药物与辅料的相容性。选取的自变量为虾虾油（PO）：吐温80：丙二醇（PG）、搅拌时间（ST）和超声时间，选取的因变量为球状尺寸和PDI。结果F15a &；F15b的粒径分别为280.23±0.21和276.45±0.29 nm， pdi分别为0.390±0.02和0.593±0.02，zeta电位分别为-65.43±0.39和-70.73±0.63 mV，证实了配方的粒径分布均匀和稳定性。与普通药物相比，配方F15a和F15b对金黄色葡萄球菌的抑制作用更大(38 &；35毫米)和大肠杆菌（32&；29毫米）。透射电镜分析显示，球的形状接近球形，没有合并。体外释药数据显示，F15a和F15b的体外释药时间长达72 h， CPL的体外释药率分别为92.4%和95%，CUR的体外释药率分别为87.6%和94%。采用等高线图选择所需的批范围。稳定性研究表明，该配方在40±2°C和75±5%的相对湿度下保持稳定。与对照组（70.00±0.18%）和标准组（92.04±0.84%）相比，优化后的ne - cpll - cur水凝胶F15a &；f15b处理组伤口收缩更大(94.44±0.56；（99.08±0.18%）。组织病理学研究显示更好和改善的再上皮和表皮和真皮再生。结论本研究结果表明，发育的ne - cpll - cur (0.5:1；CPL和CUR)壳聚糖基水凝胶由于协同作用的结合以及纳米乳中存在的虾蛄油，提供了更好的伤口愈合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-

CiteScore

3.70

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.